Breaking News, Trials & Filings

Regeneron’s COVID-19 Antibody Cocktail Gets EUA

Expects to have treatment doses ready for approximately 80,000 patients by the end of November, and 200,000 by the first week of January.

By: Contract Pharma

Contract Pharma Staff

Regeneron Pharmaceuticals, Inc. received Emergency Use Authorization (EUA) from the U.S. FDA for its antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19. Casirivimab and imdevimab are authorized to treat mild to moderate COVID-19 in adults and pediatric patients at least 12 years of age who have tested positive for SARS-CoV-2 and are at high risk for progressing to severe COVID-...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters